Inhaled pyrazinamide proliposome for targeting alveolar macrophages

Drug Delivery

Volumn 19, Issue 7, 2012, Pages 334-345

  Rojanarat, W ^a   Nakpheng, T ^a   Thawithong, E ^a   Yanyium, N ^a   Srichana, T ^a  

^a PRINCE OF SONGKLA UNIVERSITY   (Thailand)

Author keywords

Dry powder inhaler; immunological response; liposome; pulmonary; tuberculosis

Indexed keywords

CHOLESTEROL; INTERLEUKIN 1BETA; LIPOSOME; MANNITOL; NITRIC OXIDE; PHOSPHATIDYLCHOLINE; PYRAZINAMIDE; TUMOR NECROSIS FACTOR ALPHA;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; ENCAPSULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; INFRARED SPECTROSCOPY; LIVER TOXICITY; LUNG ALVEOLUS MACROPHAGE; MALE; MYCOBACTERIOSIS; NEPHROTOXICITY; NONHUMAN; PHYSICAL CHEMISTRY; POROSITY; POWDER INHALER; PRIORITY JOURNAL; RAT; SPRAY DRYING; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; CALORIMETRY, DIFFERENTIAL SCANNING; CELLS, CULTURED; HUMANS; INTERLEUKIN-1BETA; LIPOSOMES; MACROPHAGES, ALVEOLAR; MALE; MANNITOL; NITRIC OXIDE; PARTICLE SIZE; PHAGOCYTOSIS; PYRAZINAMIDE; RATS; RATS, WISTAR; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TUMOR NECROSIS FACTOR-ALPHA; X-RAY DIFFRACTION;

EID: 84867567038     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2012.721144     Document Type: Article

References (31)

1. Agnihotri SA, Soppimath KS, Betageri GV. 2010. Controlled release application of multilamellar vesicles: a novel drug delivery approach. Drug Deliv 17:92-101.
2. Ahsan F, Rivas IP, Khan MA, Torres Suarez AI. 2002. Targeting to macrophages: role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 79:29-40. (Pubitemid 34164159)
3. Alving CR. 1998. Macrophages as targets for delivery of liposomeencapsulated antimicrobial agents. Adv Drug Deliv Rev 2:107-128.
4. Atkins PJ, Barker NP, Mathisen D. 1992. The design and development of inhalation drug delivery systems. In: Pharmaceutical Inhalation Aerosol Technology. Hickey AJ (Ed.). Marcel Dekker: New York, USA.
5. Brain JD, Knudson DE, Sorokin SP, Davis MA. 1976. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. Environ Res 11:13-33.
6. Castro RAE, Teresa MRM, Evora AOL, Feiteira JC, Silva MR, Beja AM, Canotilho J, Eusebio MES. 2010. A new insight into pyrazinamide polymorphic forms and their thermodynamic relationships. Cryst Growth Des 10:274-282.
7. Changsan N, Chan HK, Separovic F, Srichana T. 2009a. Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation. J Pharm Sci 98:628-639.
8. Changsan N, Nilkaeo A, Pungrassami P, Srichana T. 2009b. Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages. J Drug Target 17:751-762.
9. Crowder TM, Rosati JA, Schroeter JD, Hickey AJ, Martonen TB. 2002. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' law and the particular relevance to dry powder inhaler formulation and development. Pharm Res 19:239-245. (Pubitemid 34211838)
10. Elhissi AM, Faizi M, Naji WF, Gill HS, Taylor KM. 2007. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 334:62-70. (Pubitemid 46400313)
11. Elhissi AMA, Islam MA, Arafat B, Taylor M, Ahmed W. 2010. Development and characterisation of freeze-dried liposomes containing two anti-asthma drugs. Micro & Nano Letters 5:184-188.
12. Heurtault B, Saulnier P, Pech B, Proust JE, Benoit JP. 2003. Physicochemical stability of colloidal lipid particles. Biomaterials 24:4283-4300. (Pubitemid 36814076)
13. Thompson DC. 1992. Pharmacology of therapeutic aerosols. In: Pharmaceutical Inhalation Aerosol Technology. Hickey AJ (Ed.). Marcel Dekker: New York, USA.
14. Huttunen K, Ruotsalainen M, Iivanainen E, Torkko P, Katila M, Hirvonen M. 2000. Inflammatory responses in RAW264.7 macrophages caused by mycobacteria isolated from moldy houses. Environ Toxicol Pharmacol 8:237-244.
15. Johnston DE. 1999. Special considerations in interpreting liver function tests. Am Fam Physician 59:2223-2230. (Pubitemid 29197947)
16. Kanchan V, Panda AK. 2007. Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. Biomaterials 28:5344-5357. (Pubitemid 47532191)
17. Khuller GK, Kapur M, Sharma S. 2004. Liposome technology for drug delivery against mycobacterial infections. Curr Pharm Des 10:3263-3274. (Pubitemid 39276614)
18. Mitchison DA, Fourie PB. 2010. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edinb) 90:177-181.
19. Morris KR, Rodriguez-Hornedo N. 1993. Hydrates. In: Encyclopedia of Pharmaceutical Technology. Swarbrick J, Boylan JC (Eds.). Marcel Dekker: New York, USA. 393-440.
20. Nolan LM, Tajber L, McDonald BF, Barham AS, Corrigan OI, Healy AM. 2009. Excipient-free nanoporous microparticles of budesonide for pulmonary delivery. Eur J Pharm Sci 37:593-602.
21. Pandey R, Sharma S, Khuller GK. 2004. Nebulization of liposome encapsulated antitubercular drugs in guinea pigs. Int J Antimicrob Agents 24:93-94. (Pubitemid 38844571)
22. Punturee K, Wild CP, Vinitketkumneun U. 2004. Thai medicinal plants modulate nitric oxide and tumor necrosis factor-alpha in J774.2 mouse macrophages. J Ethnopharmacol 95:183-189. (Pubitemid 39422668)
23. Rojanarat W, Changsan N, Tawithong E, Pinsuwan S, Chan HK, Srichana T. 2011. Isoniazid proliposome powders for inhalationpreparation, characterization and cell culture studies. Int J Mol Sci 12:4414-4434.
24. Ross PD, Rekharsky MV. 1996. Thermodynamics of hydrogen bond and hydrophobic interactions in cyclodextrin complexes. Biophys J 71:2144-2154. (Pubitemid 26325994)
25. Saetern AM, Flaten GE, Brandl M. 2004. A method to determine the incorporation capacity of camptothecin in liposomes. AAPS PharmSciTech [Online] 5:1-8. http://www.aapspharmscitech.org. Accessed on 14 September 2010.
26. Salfinger M, Heifets LB. 1988. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 32:1002-1004.
27. Sharp PE, LaRegina MC. 1998. The laboratory rat. In: The Laboratory Animal Pocket Reference Series. Suckow MA (Ed.). CRC Press LLC: Florida, USA. 17.
28. Srichana T, Suedee R, Srisudjai P. 2003. Application of spectrofluorometry for evaluation of dry powder inhalers in vitro. Pharmazie 58:125-129. (Pubitemid 36267916)
29. Taylor K, Elhissi A. 2006. Preparation of liposomes for pulmonary delivery using medical nebulizers. In: Liposome Technology. Kevin M, Tayler G, Abdelbary M, Elhissi A (Eds.). Informa Healthcare: London, England. 67-84.
30. USP 30 and NF 25; USP-NF. 2007. Guideline No. 905: Uniformity of dosage units. In: US Pharmacopeia 30-NF 25. US Pharmacopeial Convention (ed.). US Pharmacopeial Convention, Inc.: Rockville, USA. 378-384.
31. Wagner A, Vorauer-Uhl K. 2011. Liposome technology for industrial purposes. J Drug Deliver . doi:10.1155/2011/591325. http://www. hindawi.com. Accessed on 11 July 2011.